# Effect of Topical Calcipotriene/Betamethasone (Taclonex) in Managing Localized Breakthrough in Moderate to Severe Plaque Psoriasis in Patients Receiving Efalizumab (Raptiva)

> **NCT00608777** · PHASE4 · TERMINATED · sponsor: **Derm Research, PLLC** · enrollment: 6 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** Calcipotriene/betamethasone

## Key facts

- **NCT ID:** NCT00608777
- **Lead sponsor:** Derm Research, PLLC
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-01
- **Primary completion:** 2009-02
- **Final completion:** 2009-02
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Withdrawal of marketing autorization of efalizumab by the EMEA.
- **Last updated:** 2012-08-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00608777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00608777, "Effect of Topical Calcipotriene/Betamethasone (Taclonex) in Managing Localized Breakthrough in Moderate to Severe Plaque Psoriasis in Patients Receiving Efalizumab (Raptiva)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00608777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*